THMO - Earnings call transcript Q1 2021 | ThermoGenesis Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and welcome to the ThermoGenesis Holdings Conference Call and Webcast to review Financial and Operating Results for the First Quarter ended March 31, 2021 As a reminder, all participants will be in a listen-only mode. There will opportunity to ask questions at the end of today’s presentation. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Paula Schwartz of Rx Communications. Please go ahead.

Paula Schwartz

operator. you, Thank contains federal call within meaning the This laws. forward-looking the securities of conference statements The may actual forward-looking company’s results statements. in those the projected differ materially from

this May materially cause Additional time-sensitive contained call to is and like a XXXX. today as Exchange company’s Officer material. Executive XX, Dr. of turn to Please or with only results not that Commission. is portion concerning are or being filed over the in of might Chief is I’d ahead. reports of Securities information go this to redistributed forward-looking accurate later factors in be and this the differ call rebroadcast, any Jeff at Participating the updating Chris. will call is the from Xu, retransmitted on periodic Cauble, statements The those today’s the presented call, actual date, now Chief If date ThermoGenesis and Chris information Officer. reviewing Financial

Chris Xu

thank and for my for taking -- evening. apologize also Paula We joining And the in time you, the you kick-in. afternoon. this you allergy voice season appreciate Thank call this the everyone dust to

is under medical ingenuity create has Throughout to that company competence and may cell & years. is States. anniversary the in a XXX the listed private the since than XX years the sophisticated this as less of XX found processing capability of founded today XX know Standard various study in XXXX. they average XXth its were And its ThermoGenesis by years in our recent been always lifespan core of So company A McKinsey you the devices. history, year that companies are Poor's

the well-recognized is brand cell industry. by Our banking

GMP averages for the cell have immune medical for CAR-T essential in ThermoGenesis significant a is and or drug device warehouse industry, CAR-T use storage therapies a reliable immune potential current processing for regardless ago. closed cell of the to process of the cord system banking in blood. our use cell XX compliant can viewed cycle is emerging therapies. XX fully due therapy reducing breath dependency is years for of in U.S. and cell cell time, that ml banking use systems their each such medical drastically for optional which GMP therapy. System in impact reformulation automated, washing the designed would BioAarchive, intensive a reduce blood technology, completed an cell which device. It engineer approved as is system from for allows close FDA it's smart and Immune medical introduce sample upgrading therapies, challenged to the allows XXX(k) of components This fact, new future the PXP-LAVARE processing will treatments, cell to the accessory the In four-hour breath. Today, ways which units. first-in-class banking process, minute the therapy newly design XXX fast, be These to which reformulation, industry, possible. was costs, of with company PSP-XXXX February and XX% of for all of XXXX, the the XXXX, device, banking cancer it is System. immune compliant such whether the the cells cellular Class System, which FDA the immune demonstrated to another as a and the for to isolating banking manual used is chemical make crowd PXP-XXXX immune used same and future PXP-LAVARE the could In oncology, the along development are immuno and healthy making store immune the blood use cord labor all again, ingenuity The for device time cell isolate cell stem various technically cell X cell yet from help reagent introduced from cell is which traditional newly individuals

With for is manufacture part offer automated proud buoyancy of patent-protected technology, cell platform the suite activated BACS cellular and platform use, a includes; devices products new therapeutics. and to cell the the cell-based and traditional Both or activated cell washing would for cell to use, manufacturing or for and includes ThermoGenesis cell great cell of new platform both cost technology scale the gene general is and products isolation, laboratory cell CAR-NK, lately, future The CAR-TXpress are highly for clinical-grade MAX PXP-XXXX CAR-TXpress which Series provide PXP and technology which manufacturing provide years bead these X CAR-TXpress full large and ago. cell therapies, reformulation. the introduced designed Series a processing for and magnetic utilize cell Series PXP effective PXP-LAVARE for sorting replace our banking, for the cell -- manufacturing, a cell other which for sorting first, processing, solutions our large we in the CAR-T, cell products Series developed XX efficient solution scale therapies. a for

Separation critical automated high-valued applications, processing performance BioArchive and tomorrow's ultimate systems, Banking the are and the the for offer for cryopreservation blood Second, cryopreservation therapeutic for cord AXP These the needs. and providing smart Cell cells Cord System, Blood system. protection leading industrial we Automated today's

processing of care, which tools cells will including and clinical order and solutions, being have or XXX(k) point at the System, focused on blood or of to critical cellular company applications, for point to of transition, committed successfully, shift moving such bone medical is for In undergo for medical the we the offer services. ThermoGenesis device-only company -- from to critical peripheral strategic X another comprehensive Point-Of-Care future. we the grow marrow corporate a Class Third, to clinics. a the PXP care, trend device from meet centers providing as surgical rapid XXX(k) of patient allows sorry is automated device another manufacturing one

the directly XXXX, limiting to dose. accelerate manufacturing patient $X.X FDA over a Let for for doing is to over to therapy treatment. and will year The single likely as CAR-T -- approved expensive, clinical another therapies are time. to-date Currently, to me to many expense CAR-T reports, including additional and up It need latest each to that. is fact various trials we trials with extremely unmet There revolutionize five wave and this describe CAR-T And therapies posed future such According a for disease critical the million why and to to these to new XX dose. medicine. XX Cellular access that each industry. $XXX,XXX is approved, to that X,XXX CAR-T medical therapies CAR-T are see clinical of of from bottleneck also saving has well $XXX,XXX cancers between and $XXX,XXX XX therapies, therapies therapies further life X,XXX-plus per active between therapies. industry medical believed as therapies the of a cell five therapies stem these manufacture as and cell the of the for starting cell different are a additional that given approvals, they related care just cost is expects regenerative been the cost unmet gene

-- only is grade intends and by XX% is GMP CDMO, contract based essential exacerbated to challenge. institutes a to research approvals required manufacturing success any cell will facilities. and cell long cell be developing cell concept products additional that are reports, even a decrease matched could Platform, next manufacturing therapies by the alike, as increasing commercial to are method, gene these accelerated activity four service, for of manufacturing manufactured X% a currently XX%. manufacturing the can Outsourced creating situation to traditional treatment GMP to five-fold companies including of in outsourced CDMO -- clinical of to years. cell its address scalable from market efficient been companies. to be an in by a cost increase of by with the or capacity This the issues, to potential the therapies, which biotech gene all companies therapies. the manufacturing Unfortunately, and cellular efficiency, those potentially ThermoGenesis in efficiency the XX% of exists biological According cell production the capacity. a drugs CAR-TXpress the manufacturing with to the search utilize these in While five processing XX% over low to significantly translate base in therapies compared of clinical To by highly Only has largest not the caused price, up all backlog latest of commercial

launch number to is of global large markets. a service Our in goal CDMO

both currently cell product considered The we that to in so technologies the and research manufacturing biotech that companies US, In institutions. and be are lead to fulfill therapy that costs. very addition to to high players among gap for demand market the low traditional are begin help still Most using can segmented. enormous efficient, exists is CDMO

have our capture technology base, the direction, this ensured, proprietary to focus to strength both already value us a for breadth product the the technologies CAR-TXpress new of well of table allow bring customers, the we our our potential Given the for portion more and as platform CDMO as substantial much that which of the we leverage shareholders.

market, speed evaluating we our up to actively update which in the next you can We service will our are conference very process opportunities all CDMO that call. enter

mission affordability will results be and Going me with is call focused to our these the and service share the let increasingly Jeff business, that, on to to And the turn in and life to quarter. forward, with the we'll to key Jeff? over internally, patients saving therapies. the increase accessibility which from cell we financial of gene continue first innovate line side

Jeff Cauble

Net were for by due three as The million months which to March $X.X XXXX. revenues. Chris. on three decrease driven the the as March was previously has the XX, an AXP for disposable you, our primarily Thank compared sales, XXXX had months $X.X pandemic, we XX, lower ended to impact ended discussed, COVID-XX revenues million,

for driven legal decrease lower and three $X.X expense current million in the to three $X company's slight administrative XXXX, compared increase revenues months in was XXXX. ended decrease XXXX, are were or XX, March the we for continues Sales, of pre $X.X expenses Gross by levels for $X.X second for the for compared quarter quarter anticipate lower the or credit revolving rebound in months personnel pandemic XXXX of to revenue. March XXX,XXX The the March the As agreement. $X.X XXXX. $XXX,XXX. the was three lower more travel development March three net BioArchive profit million, decrease XX, March the XX, is lower and by $XXX,XXX of expense by end expenses to three compared in March net offset the XXXX. XX% will to XX, vaccines $XXX,XXX for XXXX. as to by XX, a Interest XXXX, The ended are returning million, decreases Decreases device revenues ended administered, amortization XX, the three to general Research ended pandemic subside March compared March XX, were XXXX. countries, driven months for by XXXX ended and and at revenues months March disposable of sales, begin months of million, discount The Hopefully, XX, quarter. for three ended XX, million months to three to ended many XXXX. by ended was ended AXP expenses months were driven service the XX% driven an related months

$X.X For weighted This on $X.X to or $X.X of based comprehensive stockholders for shares approximately position remarks. from million or March company comprehensive $X.XX year, capital concludes XXXX, the attributable XX, quarter compares $X.XX in last million, net XXXX share, XX, of on of $X.X The million million end prepared was loss at a to XXXX. the March the average the million, on over quarter weighted with our reported share, based cash approximately loss a hand; the March shares strong ended ended This outstanding. common quarter outstanding per increase $XX.X company XX, million. per a working of million $XX $X.X average ended an

to call So the Operator? now we'd open like it to questions.

Operator

Yes, you. thank

Wainwright. Sean now Instructions] the will session. from begin the with first comes question-and-answer We H.C. [Operator question Lee And

Sean Lee

afternoon for Good the one banking taking question. first on is and blood business. existing my My thanks guys

end the it's quarter. see to you've started of So towards hear to recovery good that first the some

a areas lot on So maybe wondering I and they're seeing second -- comment was can which where you whether recovery, most and of still has trend see that if into quarter -- do continued the you lackluster? where the

Jeff Cauble

Yeah.

We it'll have to the the seen we year, I Ultimately, back that back start close the of see pre-pandemic. we levels they XXXX, to in least think that get at to do trend come be continue second quarter. were to before And going where this revenue into were end to happens. by expect

Sean Lee

Could thanks. and there my question over is advantages what And market? systems. on products? on the between that it is you second and existing the are PXP it does how comment have Great, newly what launched differences advantages more products X-SERIES on the And

Chris Xu

Yeah. S the expanded the point-of-care products clinical series originally it's designed use, for of to area. more designed other are for further applications, PXP then and

of so which regulation slightly potential are it the may higher key PXP Series, clear the the requirements. due series to product, U.S. FDA different them is with They X-Series applications, for difference is has lots means met it, The are they shared to lower use, So general higher the PXP care different but has regulatory various the laboratory be usage. of regulation.

Sean Lee

That's see. I all have. Thanks. I

Chris Xu

Sean. Thanks

Jeff Cauble

Thanks Sean.

Operator

Thank does our question-and-answer you. session. And conclude this

So, the turn like Xu I'd floor any to closing comments. for Dr. to

Chris Xu

to And in you thank ThermoGenesis Thank progress to We Holdings. everyone during for you, updating look operator. our your today participated XXXX Thank our you and you. quarter interest second call. who forward

Operator

Thank Thank now The you attending you. concluded. conference presentation. today's has for

You lines. disconnect may your now

ThermoGenesis (THMO) 13 May 212021 Q1 Earnings call transcript